**Supplementary data**

**Table 1.** Differences between patients without any or with at least one missing value.

|  |  |  |
| --- | --- | --- |
|  | No missing values | ≥1 missing value |
| Sex (n, %) Male Female | 82 (63)48 (37) | 112 (62)68 (38) |
| Age (median, IQR) | 66 (60-73) | 69 (67-75) |
| KPS (median, IQR) | 70, (60-80) | 70 (60-71) |
| VFA (median, IQR) | 133 (85-213) | 16 (78-205) |
| SFA (median, IQR) | 157 (108-250) | 160 (110-215) |
| VFA/SFA-ratio (median, IQR) | 0.87 (0.53-1.16) | 0.83 (0.49-1.36) |
| SMI (mean, SD) | 51 (9.8) | 51 (8.5) |
| MA (mean, SD) | 29 (6.5) | 29 (6.5) |
| Sarcopenia (n, %) | 68 (52) | 44 (24) |
| Primary tumor (n, %) Lung Prostate Breast Other | 33 (25)22 (17)34 (26)41 (32) | 53 (29)33 (18)49 (27)45 (25) |
| Multiple bone metastases (n, %) | 75 (58) | 114 (63) |
| Non bone metastases (n, %) Liver Brain | 66 (51)33 (25)5 (4) | 86 (48)37 (21)4 (2) |
| Neurological symptoms (n, %) | 10 (8) | 18 (10) |
| Abbreviations: IQR: interquartile range, KPS: Karnofsky Performance Scale, VFA: visceral fat area, SFA: subcutaneous fat area, SMI: skeletal muscle index, SMD: skeletal muscle density |

Figure 1. Convergence plot of imputation of missing data in patient’s height



Figure 2. Convergence plot of imputation of missing data in the Karnofsky Performance score

